Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | F2R | P25116 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23964434 | 0.92 | SIGMAR1 (0.52) | MEN1KMT2ASIGMAR1F2RCA2 | |
| SCHEMBL23964437 | 0.86 | ALDH1A1 (0.50) | SIGMAR1CA2ALOX15HSD17B10CYP2D6 | |
| SCHEMBL5323909 | 0.81 | HRH3 (0.54) | MEN1KMT2ASIGMAR1CYP2C9ALOX15 | |
| SCHEMBL23964430 | 0.78 | MAPT (0.49) | MEN1KMT2ASIGMAR1CA2CYP2C9 | |
| SCHEMBL15306596 | 0.77 | SIGMAR1 (0.57) | MEN1KMT2ASIGMAR1CYP3A4CYP2D6 | |
| SCHEMBL23926340 | 0.75 | ERN1 (0.46) | MEN1KMT2ACYP2C9ALOX15HSD17B10 | |
| SCHEMBL10454920 | 0.74 | HRH3 (0.72) | MEN1KMT2ASIGMAR1CYP2C9ALOX15 | |
| SCHEMBL24127975 | 0.73 | POLB (0.51) | MEN1KMT2ASIGMAR1CYP2C9ALOX15 | |
| SCHEMBL10154384 | 0.73 | CYP2A13 (0.63) | MEN1KMT2ACYP2C9ALOX15HSD17B10 | |
| SCHEMBL3809080 | 0.72 | CA2 (0.59) | CA2CYP2C9ATMGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155547-B1 | Compounds for and methods of treating diseases | Alterity Therapeutics Limited (AU) | 2021-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155547-B1 | Compounds for and methods of treating diseases | HTT, SNCA, PARK7 | MEN1 1161/4885KMT2A 730/4885SIGMAR1 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.